Piebaldism

Congenital leucoderma due to defective melanoblast migration (KIT; SNAI2 under discussion)

Literature and regulatory information updated: 29 October 2026.

0. Initial Reference Table

1. Introduction

1.1. Definition and scope

Piebaldism is an autosomal dominant disorder of melanocyte development, characterised by congenital patches of white skin and hair from which melanocytes are absent [25, 26]. Orphanet defines it as a rare congenital pigmentary disorder with hypopigmented and depigmented areas (leucoderma) located preferentially on the forehead, chest, abdomen, arms and lower limbs, associated with a white forelock (poliosis) and, in some cases, depigmented eyebrows and eyelashes [9]. The Oxford Desk Reference describes it as a congenital, sharply demarcated and usually symmetrical depigmentation, mainly of the anterior surfaces of the body, that often includes the forehead and the frontal forelock; its congenital and non-progressive nature distinguishes it from vitiligo [21]. The distinction between depigmentation (amelanosis, with melanocytes absent or totally non-functional) and hypopigmentation (melanocytes present but reduced in number or function) is useful: piebaldism belongs to the first group [18, 21].

The article covers KIT-associated piebaldism, which accounts for the great majority of cases, and the form attributed to heterozygous SNAI2 deletions, whose validity as an independent cause remains under discussion [3, 12, 27, 28]. It also includes the forms with deafness described as an "expanded syndrome" of piebaldism [29, 30], homozygosity for KIT variants [11, 31], the 4q12 microdeletions that remove KIT and are accompanied by intellectual disability [4, 32, 33] and the historical entity "piebald trait with neurological defects" [6, 13]. The KIT gain-of-function allelic disorders (familial gastrointestinal stromal tumour, cutaneous hyperpigmentation and mastocytosis) are treated as differential diagnoses and as a mechanistic counterpoint [1, 34]. The Waardenburg syndromes and oculocutaneous albinism enter the differential; only the distinguishing elements are given here.

1.2. Historical overview

OMIM records early family descriptions: Keeler (1934) traced a Black family from Louisiana back to a woman born in 1853, Sundfor (1939) described a family with many members with a white forelock and depigmented patches, and Comings and Odland (1966) found the trait in six generations; the painter George Catlin (1796–1872) portrayed an affected Mandan Indian, in a group in which several members would have been affected [14]. Froggatt compiled in 1959 a review with a bibliography on human piebaldism and white forelock, and another family with six affected generations was published in 1979 [35, 36]. For decades it was debated whether piebaldism was a forme fruste of Waardenburg syndrome or an autonomous entity. Bankier and Sheffield (1990) and Winship and colleagues (1991), the latter with a family of seven affected individuals in three generations without other stigmata, argued for the nosological autonomy of the condition [37, 38]. Ortonne (1988) proposed grouping piebaldism, Waardenburg syndrome and the forms with intestinal aganglionosis as "neural crest depigmentation syndromes" [39], and Kaplan and de Chaderévian described, in the same year, an Inuit infant with hypopigmentation, heterochromia, megacolon and deafness, under the designation "piebaldism–Waardenburg", with absence of melanocytes in the depigmented skin and neuronal dysplasia of the colon [40].

Genetic localisation started from patients with chromosomal deletions. Hoo and colleagues noted, in 1986, that three of four patients with a proximal interstitial deletion of 4q had abnormal skin pigmentation consistent with piebaldism and proposed band 4q12 for the gene [32]. In 1991, two groups demonstrated the role of KIT. Giebel and Spritz identified the substitution NM_000222.3:c.1990G>A p.(Gly664Arg) in the tyrosine kinase domain in a family with classic dominant piebaldism, whose transmission could be traced over 15 generations, with a lod score of 6.02 and absence in 40 controls, and presented the disease as the human homologue of mouse dominant white spotting (W) [14, 25]. Fleischman and colleagues found, in one of seven unrelated patients, a heterozygous deletion of the entire KIT gene, confirmed by fluorescence in situ hybridisation, which also included PDGFRA [41]. In the following two years the first genotype–phenotype correlations were described: a substitution NM_000222.3:c.1752T>G p.(Phe584Leu) in the kinase domain with a severe phenotype and proximal frameshifts with a mild and variable phenotype [26], and the substitution NM_000222.3:c.1747G>A p.(Glu583Lys), identical to the mouse W37 mutation, which abolishes autophosphorylation and causes more extensive depigmentation than null alleles, establishing the concept of a dominant-negative effect [42, 43].

In 2003, Sánchez-Martín and colleagues looked for SLUG (SNAI2) alterations in 17 patients without a KIT variant and found heterozygous deletions of the entire coding region in three, which led to the inclusion of SNAI2 among the piebaldism genes [12]. The same team had described, the previous year, homozygous SNAI2 deletions in two patients with Waardenburg syndrome type 2 [44]. Neither finding has been consistently replicated; in 2020, Mirhadi, Spritz and Moss published a letter entitled "Does SNAI2 mutation cause human piebaldism and Waardenburg syndrome?"; the ClinGen hearing loss gene curation expert panel classifies the SNAI2–Waardenburg relationship as "limited", and OMIM has reclassified the SNAI2 deletion described in piebaldism as a variant of uncertain significance, keeping KIT as the only gene associated with entry 172800 [3, 14, 28].

1.3. Nomenclature

The term "piebaldism" replaced "partial albinism", a designation still found in older texts and which is misleading, because albinism is a defect of melanin synthesis with melanocytes present, whereas piebaldism is a defect of melanoblast migration and survival with melanocytes absent [10, 18]. The English term piebald trait is a synonym [41]. Congenital circumscribed poliosis (white forelock) is the cardinal sign, but it is not specific to piebaldism: it also occurs in the Waardenburg syndromes, in vitiligo, in halo naevi and, as described in 2026, in carriers of germline BAP1 variants [45, 46].

2. Molecular Genetics and Pathophysiology

2.1. Melanocyte biology and the embryological origin of the pattern

The skin pigments, eumelanin and pheomelanin, are produced in melanosomes by melanocytes, cells of the basal layer of the epidermis derived from the neural crest, and transferred to keratinocytes [21]. Oiso and colleagues break skin colour down into seven steps: migration of melanoblasts in the embryo, proliferation and survival of melanocytes in the basal layer, melanosome biogenesis, melanin synthesis, translocation of melanosomes to the periphery of the melanocyte, transfer to keratinocytes and supranuclear translocation of the granules within them [10]. Piebaldism results from a failure of the first step: melanoblasts arise in the neural crest, in a dorsal position, and migrate ventrally; when migration or survival fails, the regions furthest from the origin (ventral midline, forehead, mid-portion of the limbs) are left without melanocytes after birth [10, 18]. During embryogenesis, KIT ligand produced in the dermomyotome binds to the KIT receptor of melanoblasts and allows their survival and migration throughout that territory [18]. The observation of contiguous and asymmetrical depigmentation crossing both legs in two patients led Funkhouser, Kinsler and Frieden to propose that some limb melanocytes have a mesodermal origin and migration, which the classic theory of unilateral migration from the neural crest does not explain [47].

2.2. The KIT gene and the receptor

KIT (4q12; OMIM 164920; MANE transcript NM_000222.3, protein NP_000213.1) encodes the type III receptor tyrosine kinase CD117, the receptor for stem cell factor (SCF, also called KIT ligand, KITLG, Steel factor or mast cell growth factor) [1, 2]. SCF binding causes receptor dimerisation, autophosphorylation of tyrosine residues and activation of the PI3K-AKT, RAS-MAPK, PLCγ and STAT pathways, which regulate haematopoiesis, stem cell maintenance, gametogenesis, melanocyte development and migration, and mast cell development and function [1, 20]. In melanocytes, KIT signalling takes part in migration, proliferation, differentiation, survival, melanogenesis and melanosome transfer [10, 34]. The main autophosphorylation residues are Tyr568 and Tyr570, in the juxtamembrane region; Tyr900, in the second kinase domain, binds the p85 subunit of PI3K [20].

The protein is organised into a signal peptide (residues 1–22), an extracellular ligand-binding domain with five immunoglobulin-like loops (23–520), a transmembrane domain (521–543), a juxtamembrane domain (544–581) and a tyrosine kinase domain split into two lobes, TK1 (582–684) and TK2 (762 to the carboxyl terminus), separated by a kinase insert (685–761) [10, 20]. Sources differ on the final boundary of TK2 (residue 937 in one, 973 in another); the activation loop, with the most conserved enzymatic residues, lies between 810 and 839 [10, 20].

2.3. Mechanisms: haploinsufficiency and dominant-negative effect

Piebaldism results from KIT loss of function, with two mechanisms that explain much of the variation in severity [10, 26, 42]. In haploinsufficiency, the mutant allele produces no receptor (gene deletion, nonsense variant with messenger RNA decay, proximal frameshift) or produces a receptor that does not reach the membrane or does not bind SCF (missense in the extracellular domain); about 50% of function is preserved and the phenotype is mild [10, 48]. In the dominant-negative effect, the mutant receptor reaches the membrane and dimerises with the normal receptor, but the heterodimer does not transmit a signal; as only a quarter of the dimers are formed by two normal chains, residual function is about 25% and the phenotype is severe [10, 20, 48]. The canonical example is NM_000222.3:c.1747G>A p.(Glu583Lys), identical to the mouse W37 mutation, whose murine phenotype is more severe than that of null alleles [42]. Functional studies in HEK293T cells showed that p.(Glu583Lys) and NM_000222.3:c.2716T>C p.(Cys906Arg) reduce AKT and ERK phosphorylation after SCF stimulation [20]; the in-frame deletion NM_000222.3:c.645_650del p.(Val216_Ser217del), in the extracellular domain, forms heterodimers but reduces downstream phosphorylation and is retained in the endoplasmic reticulum, in a Japanese family with a mild phenotype [49]. The original p.Gly664Arg variant and the p.Phe584Leu variant, both in TK1, were associated with a severe phenotype [25, 26].

GeneGuidance records for KIT a ClinGen haploinsufficiency score of 3, consistent with the coexistence of loss-of-function and dominant-negative alleles [1]. The link between haploinsufficiency and piebaldism is not, however, absolute: Hemati and colleagues described a patient with a 4q12-q21.21 deletion that included KIT and who did not have piebaldism, and concluded that the mechanism is more complex than simple gene dosage [33].

2.4. Variant spectrum

A 2024 review counted 99 KIT variants associated with piebaldism: 59 missense (59.6%), 15 frameshift, 11 splicing, 5 nonsense, 4 in-frame insertions or deletions, 1 large intragenic deletion, 3 chromosomal microdeletions including the entire gene and 1 pericentric inversion inv(4)(p16q12) [20, 50]. Point variants and small insertions or deletions are concentrated in the TK1 and TK2 domains [20]. Oiso and colleagues had counted, up to 2012, 32 missense, 17 deletions, 4 insertions, 7 splicing, 2 nonsense and 1 inversion [10]. The 12-base-pair deletion described in a large Italian family in 1995 and a recurrent KIT deletion reported by Spritz in 1993 show that small recurrent deletions also occur [51, 52]. Splicing variants outside the canonical ±1/2 positions can be causal: in 2026 an intronic insertion NM_000222.3:c.1990+8_1990+9insTGCACCATTGGAGGTAAA was described which, by reverse transcription followed by polymerase chain reaction (RT-PCR), introduces 21 nucleotides into the messenger RNA and adds 7 amino acids to the kinase domain, classified as likely pathogenic [53]. In October 2026 ClinVar held 168 KIT records with the term piebaldism, of which 16 pathogenic, 8 likely pathogenic, 1 pathogenic/likely pathogenic, 54 of uncertain significance and 62 with conflicting classifications; some of the conflicts reflect submissions from oncological and somatic contexts [54].

Table 2.1 summarises variants cited in this article, normalised in VariantValidator on the MANE transcript and with the ClinVar classification at the date of consultation.

In Table 2.1, the nomenclature used in the original articles (for example, NM_000222.2 in the cases of Nagaputra and Budair) was converted to NM_000222.3 only by validation in VariantValidator, with no change in nucleotide number for the variants checked [2].

2.5. Genotype–phenotype correlations

The severity of piebaldism is classified by extent: mild when there is only a white forelock or small guttate leucoderma on the ventral trunk and limbs; severe when the typical forelock is accompanied by large patches on the chest, abdomen and limbs; moderate in intermediate cases [20]. In the 2024 review, about 90% of variants in the TK1 and TK2 domains were associated with severe depigmentation and all variants in the signal peptide and in the extracellular, transmembrane, juxtamembrane and kinase insert domains with a mild or moderate phenotype; the three patients with deletion of the entire gene had a mild to moderate phenotype [20]. Among the 59 carriers of missense variants, 27 (45.8%) had café-au-lait macules, 3 (5.1%) brown hair, 2 (3.4%) iris heterochromia and 1 (1.7%) deafness [20]. In an independent review of 88 cases with a KIT variant published up to December 2022, 27 (30.7%) had café-au-lait macules, of whom 24 with a severe phenotype and 26 with a variant in the kinase domain (96%); a severe phenotype was associated with a 6.353-fold greater probability of café-au-lait macules (95% confidence interval, 1.728–23.363) [48]. Fleischman and colleagues showed that missense variants in the extracellular domain (published protein designations, NP_000213.1 numbering: p.Cys136Arg, p.Ala178Thr) cause piebaldism, with a milder phenotype than null or kinase-domain variants [58], and Spritz and colleagues described a continuous spectrum of phenotypes proportional to the predicted impact of each variant on total signalling [43].

The exceptions are numerous. An Indian family with p.Leu611Phe (published protein designation, NP_000213.1 numbering), in the kinase domain, had a mild phenotype; in a Japanese family with the recurrent p.Phe584Leu variant, two children had a mild or moderate phenotype and the father, a carrier, had neither leucoderma nor poliosis, only café-au-lait macules [10, 59, 60]. Oiso and colleagues propose three explanations: modifier genes, reduced expression of the mutant allele due to another variant or epigenetic modification, and substitution by a similar amino acid [10]. Intrafamilial variability with the same variant is documented [61, 62].

2.6. Penetrance, modifiers and homozygosity

The leucoderma of piebaldism was considered fully penetrant; the family with p.Phe584Leu and a father without leucoderma shows that penetrance may be incomplete [10]. StatPearls describes piebaldism as autosomal dominant with incomplete penetrance and variable expressivity [18]. One identified modifier is MC1R: a Japanese patient with p.Pro832Leu in KIT (NP_000213.1) and homozygosity for the dysfunctional MC1R variant p.Ile120Thr (NP_002377.4; published protein designations) had reddish-brown hair outside the forelock, fair skin on the back and multiple café-au-lait macules; the expected frequency of this homozygosity in the Japanese population is 0.000441 (1 in 2268), and the authors attribute the hair colour to the combination of the two alterations [10].

Homozygosity produces a more severe phenotype. Hultén and colleagues described in 1987 a severely affected child, born to consanguineous parents both with piebaldism, interpreted as homozygous, without hair or pigmentation and with blue irides, and concluded that inheritance was intermediate [11, 14]. In 2013, Kilsby and colleagues reported proven homozygosity for a KIT variant, with depigmentation of skin and hair, deafness, developmental delay and autism spectrum disorder [31].

2.7. SNAI2 (SLUG)

SNAI2 (8q11.21; OMIM 602150) encodes a zinc-finger transcriptional repressor of the Snail family, which binds E-box sequences, represses CDH1, BRCA2 and ITGA3, is required for neural crest formation and migration and acts downstream of TWIST1 and TGFB1 in the epithelial–mesenchymal transition [3]. In the mouse, Slug mutations cause anaemia, infertility, a white forehead blaze and ventral depigmentation, a phenotype similar to that of W mutants [12]. In humans, the evidence is limited to whole-gene deletions: heterozygous in 3 of 17 patients with piebaldism without a KIT variant (Southern blot, quantitative polymerase chain reaction and, in one case, fluorescence in situ hybridisation) and homozygous in two patients with Waardenburg syndrome type 2 [12, 44]. The same team showed that MITF transactivates the SLUG promoter and that Slugh and Kit interact genetically in the mouse [44]. Isolated reports followed (a deletion and a two-nucleotide variant reported as causal) and a 2014 letter entitled "SNAI2 mutation causes human piebaldism" [57, 63]. In the opposite direction, Mirhadi, Spritz and Moss questioned in 2020 the causality of SNAI2 in piebaldism and Waardenburg syndrome, the ClinGen hearing loss expert panel classifies the SNAI2–Waardenburg relationship as limited, and OMIM has reclassified the heterozygous SNAI2 deletion described in piebaldism as a variant of uncertain significance; phenotype entry 172800 lists only KIT [3, 14, 28]. According to OMIM, Mirhadi and colleagues raised the hypothesis of a technical artefact, reported that one of the three patients with a SNAI2 deletion actually had a heterozygous KIT variant (NM_000222.3:c.2665A>G p.(Met889Val)) and cited a child with a heterozygous 1.7-Mb deletion at 8q11.1q11.21, including the whole of SNAI2, without pigmentary anomalies, deafness or dysmorphism; the homozygous deletion described in Waardenburg syndrome type 2 was also reclassified as of uncertain significance [64]. OMIM also records a Chinese girl with X-linked hypohidrotic ectodermal dysplasia due to an EDA1 variant and piebaldism attributed by the authors to a two-nucleotide substitution in the 5' untranslated region of SNAI2 [63, 64]. No difference has been described in the pattern, distribution or extent of the patches between patients with KIT or SNAI2 alterations [20]. In practice, a heterozygous SNAI2 finding on a panel is interpreted with caution, in the light of the KIT, PAX3, MITF and SOX10 results [3].

2.8. Allelic disorders and the ligand gene

Germline KIT gain-of-function variants produce the opposite phenotype: constitutive, ligand-independent activation in the interstitial cells of Cajal and in mast cells, with familial gastrointestinal stromal tumour (GIST) (OMIM 606764), diffuse cutaneous hyperpigmentation, multiple lentigines, café-au-lait macules and cutaneous mastocytosis (OMIM 154800) [1, 65, 66]. Nishida and colleagues described in 1998 the first Japanese family with multiple GISTs and a germline KIT variant: seven affected individuals in four generations, mostly benign tumours and perineal hyperpigmentation in two members [65, 67]. In an Italian family with the germline variant p.Val559Ala (published protein designation, NP_000213.1 numbering), the hyperpigmented macules of the 14-year-old son corresponded to cutaneous mastocytosis, and the father developed multiple GISTs at 18 years [67]. In 2026, Zhou and colleagues reported a family with progressive hyperpigmentation and generalised lentigines due to KIT NM_000222.3:c.2485G>C p.(Ala829Pro), with GIST in the father at 54 years, and noted that KIT-associated GISTs typically arise between 40 and 60 years [34]. Somatic KIT variants are present in about 85% of sporadic GISTs, in systemic mastocytosis, in acute myeloid leukaemias and in germ cell tumours; a KIT variant found in a tumour does not prove a hereditary syndrome, and a germline loss-of-function variant does not carry the implications of oncogenic variants [1, 66]. Imatinib and other tyrosine kinase inhibitors that block KIT cause hypopigmentation as a benign adverse effect, which pharmacologically reproduces the mechanism of piebaldism [10].

KITLG (12q21.32; OMIM 184745) encodes KIT ligand. Its variants cause three conditions: autosomal dominant deafness 69 (DFNA69), unilateral or asymmetrical, with non-specific pigmentary changes in only 3 of 14 patients in a French series; Waardenburg syndrome type 2F, classified as autosomal recessive in OMIM, with a biallelic series that includes "stocking and glove" hypomelanosis, progressive repigmentation or generalised hypomelanosis, and auditory–pigmentary presentations similar to piebaldism; and familial progressive hyperpigmentation with or without hypopigmentation (FPHH, OMIM 145250), with café-au-lait macules, lentigines and hypopigmented macules [10, 68]. Ezoe and colleagues found no alterations of the ligand gene in patients with typical piebaldism without a KIT variant [27].

3. Clinical Spectrum and Manifestations by System

3.1. Skin and hair: the typical phenotype

The leucoderma and poliosis are present at birth and follow a ventral and midline pattern [9, 18]. The most frequent finding is the triangular white forelock, described in up to 90% of patients, over a depigmented area of the central forehead and frontal scalp that often extends to the glabella and nasal bridge; the eyebrows and medial eyelashes may be white [10, 18]. The body patches are distributed over the anterior chest and abdomen and the mid-portion of the limbs, with a tendency to symmetry [18, 21]. The patches are sharply demarcated and contain islands of normally pigmented or darker skin, frequent on the elbows, knees and central anterior chest; the presence of hyperpigmented borders and islands is considered characteristic [17, 18, 69]. Leucotrichia may affect axillary and pubic hair and, in extensive forms, all body hair [20, 70]. Leucotrichia reflects the congenital absence of follicular melanocytes and is, as a rule, stable and irreversible [45].

3.2. Severity and variability

The extent ranges from an isolated forelock or small guttate patches on the ventral trunk to depigmentation of 70–80% of the body surface with total poliosis, as in the Saudi family described by Hamadah and colleagues [20, 30]. Mild forms may have no white forelock [10]. Severity depends mainly on the site and type of variant (see 2.5), but varies within the same family [61, 62].

3.3. Café-au-lait macules and freckling

Piebaldism is frequently accompanied by café-au-lait macules, which may appear at the borders or within the depigmented areas or on normal skin, and by axillary or inguinal freckling [10, 20]. In reviews of cases with a KIT variant, the frequency of café-au-lait macules was 30.7% (27/88) and 45.8% among carriers of missense variants (27/59), almost always with kinase-domain variants and a severe phenotype [20, 48]. Several patients met the NIH clinical criteria for neurofibromatosis type 1 (NF1) — six or more café-au-lait macules and freckling — without a variant in NF1 or SPRED1 [57, 71, 72]. Stevens and colleagues observed, in an extended family, that only the two members of mixed ancestry met these criteria, and the authors speculated about differences in melanosome distribution and size [71]. Chiu and colleagues proposed that KIT kinase-domain variants prevent SPRED1 phosphorylation, with insufficient suppression of the RAS-MAPK pathway, which would explain the overlap with Legius syndrome [57, 73]. The question of the coexistence of piebaldism and NF1 is debated: some authors accept coexistence when there are neurofibromas or an NF1 variant [74, 75], whereas Spritz considers that café-au-lait macules and freckling are part of typical piebaldism and are not sufficient for a diagnosis of NF1 [76, 77]. In 2026, a case was published of a fair-skinned infant with piebaldism and café-au-lait macules, presented as a pitfall in the differential diagnosis between NF1 and Legius syndrome [78].

3.4. Eye and ear

Iris heterochromia and sensorineural deafness are rare in piebaldism and, when present, require consideration of Waardenburg syndrome [17, 20]. OMIM notes that the idea that deafness is never part of piebaldism may not be accurate: Reed and colleagues (1967) described profound deafness in two patients, some patients in the Comings and Odland family were deaf, and Mahakrishnan and Srinivasan (1980) reported, in India, Hirschsprung disease in two siblings with a white forelock, depigmentation of the upper limbs, hypopigmentation of the trunk and heterochromia, children of a father with a white forelock [14]. In the 2024 review, heterochromia was described in 2 of 59 carriers of missense variants and deafness in 1 [20]. Spritz and Beighton described in 1998 a South African Xhosa girl with severe piebaldism and congenital profound sensorineural deafness, with the variant NM_000222.3:c.2386A>G p.(Arg796Gly) in the kinase domain, and proposed an "expanded syndrome" of piebaldism [29]. In the Saudi family with p.(Ala608Asp), the father noticed heterochromia only in adulthood and one of the sons had right-sided sensorineural hearing loss [30]. A Turkish girl with NM_000222.3:c.1990+2T>G had a 15% hearing loss in the right ear, according to the 2024 review [20]. In Albanian monozygotic twins with congenital deafness, a neuropsychiatric deficit and pigmentary defects, genetic analysis showed a KIT splicing variant (NM_000222.3:c.2484+5G>T) and a 15q13.3 deletion responsible for the neuropsychiatric picture, the first multilocus diagnosis described in piebaldism [79]. Recent reviews continue to describe typical piebaldism without auditory or ocular changes [61, 80].

3.5. Course: stability, progression and regression

The patches are stable throughout life and grow in proportion with the body; the absence of progression distinguishes piebaldism from vitiligo [18, 21, 70]. There are documented exceptions. Richards and colleagues described a mother and daughter with the variant NM_000222.3:c.1859T>C p.(Val620Ala) and progressive depigmentation, with progressive appearance of hyperpigmented macules; a transgenic mouse with the same variant reproduced the patch pattern but not the postnatal progression [55, 81]. Regression is also possible: spontaneous repigmentation in an infant, regression of the white forelock in a familial case and in an infant, expansion and contraction of the hypomelanotic areas in one patient, and extensive repigmentation of the body patches between 8 months and 7 years in a Saudi girl with the c.1991-2A>G variant, who also developed café-au-lait macules and whose forelock hair remained white [56, 82–85]. StatPearls describes spontaneous repigmentation as rare [18].

3.6. Absence of systemic manifestations and described associations

Isolated piebaldism has no extracutaneous manifestations and a normal life expectancy [3, 18, 61]. Depigmented skin, lacking melanin, is more sensitive to ultraviolet radiation; reviews report an increased risk of sunburn and skin cancer in the depigmented areas, although the sources consulted present no incidence data [70, 80]; Loewenthal (1959) reported epitheliomas with increased frequency in a dominant condition with white forelock and leucoderma that he called "albinoidism" [14]. Isolated associations have been published with Diamond–Blackfan anaemia, congenital dyserythropoietic anaemia type II with vaginal atresia, Rubinstein–Taybi syndrome, fragile X syndrome and glycogen storage disease 1a [86–88]; in the mouse, Kit and Slug mutations cause anaemia and infertility, which prompted these observations, but no human association has been demonstrated beyond single cases [12, 41, 89, 90].

3.7. Syndromic forms due to 4q12 deletion or rearrangement

Proximal interstitial 4q deletions that include KIT are associated with intellectual disability, multiple congenital anomalies and variable piebaldism [4, 32, 33]. Spritz and colleagues showed hemizygosity for KIT and PDGFRA in a patient with piebaldism, intellectual disability, multiple anomalies and karyotype 46,XY,del(4)(q12q21.1) [4]. A de novo pericentric inversion inv(4)(p16q12) was described in an 8-year-old boy with piebaldism, growth retardation and moderate intellectual disability [50]. Conversely, a familial 2.7-Mb microdeletion at 4q12 that includes KIT caused isolated piebaldism in several members of a family, and a patient with a 4q12-q21.21 deletion did not have piebaldism [5, 33]. The critical interval for intellectual disability lies at 4q12-q13.1 [33].

The syndrome "piebald trait with neurological defects" (OMIM 172850; ORPHA:2885) was described by Telfer and colleagues in 1971: ventral and dorsal leucoderma of the trunk, congenital white forelock, cerebellar ataxia, motor incoordination, intellectual disability of variable severity and progressive sensorineural hearing loss; Orphanet records that there have been no new descriptions since [6, 13]. One of the families had 11 affected individuals in three generations with male-to-male transmission [16]. Reassessment of the proband by Finucane and colleagues in 1991 showed fragile X syndrome, which explained the intellectual disability, without demonstrable ataxia, and Fleischman found no variants in the five KIT exons encoding most of the kinase domain in this patient; the individuality of the entity is therefore doubtful [16, 42, 87].

4. Clinical Recognition and Warning Signs

4.1. When to suspect

Piebaldism is suspected in a newborn or infant with a frontal white forelock and sharply demarcated depigmented patches on the forehead, anterior trunk and limbs, especially with a family history of a similar picture [18, 21]. For any patchy hypomelanosis, the Oxford Desk Reference proposes a history with a three-generation pedigree with specific questions about pigmentary lesions, presence since birth, increase in number or size, deafness, neurological signs, developmental delay, seizures, and Hirschsprung disease or constipation since birth [21]. On examination, the skin is photographed, and it is assessed whether the borders are sharp, whether the distribution follows Blaschko lines, whether the lesions cross the midline, and whether there is hyperpigmentation, a white forelock or premature greying, heterochromia and other lesions of tuberous sclerosis or NF1 [21].

The same work notes that, in a deaf child, the family history should include pigmentary anomalies (Waardenburg syndrome, piebaldism) and the examination should look for a white forelock and subtle cutaneous pigmentary changes, and that in Hirschsprung disease a white forelock, heterochromia and skin streaks should be sought [91, 92].

4.2. Signs pointing to another diagnosis or to a syndromic form

Signs that argue against isolated piebaldism: sensorineural deafness, heterochromia, dystopia canthorum or a high nasal root (Waardenburg syndrome); neonatal constipation or Hirschsprung disease (Waardenburg type 4 or PCWH syndrome, of peripheral demyelinating neuropathy, central leucodystrophy, Waardenburg syndrome and Hirschsprung disease); intellectual disability, ataxia or malformations (4q12 deletion or another chromosomal anomaly); lesions that appear or grow after birth (vitiligo); distribution along Blaschko lines (pigmentary mosaicism) [17, 18, 21, 33]. The presence of numerous café-au-lait macules and freckling does not exclude piebaldism, but requires consideration of NF1 and Legius syndrome [20, 71]. A congenital white forelock in an adult with a personal or family history of melanoma, uveal melanoma or other tumours should raise the possibility of BAP1 tumour predisposition syndrome: in a 2026 series, 8 of 14 carriers of germline BAP1 variants examined had chronic poliosis or depigmentation, including a patient with a white forelock since birth [46].

There are no emergency signs specific to piebaldism. Newborn screening does not include this condition.

5. Diagnosis: Criteria, Tests and Algorithms

5.1. Clinical diagnosis

There are no formal published diagnostic criteria for piebaldism. The diagnosis is clinical, based on congenital, stable leucoderma with a ventral midline distribution and a white forelock, the absence of extracutaneous manifestations and, often, a family history of vertical transmission [18, 20]. StatPearls recommends ophthalmological and neurological examination in the postnatal period to distinguish piebaldism from the syndromic forms [18]. The Oxford Desk Reference recommends clinical photography and Wood's lamp examination [21].

5.2. Wood's lamp and histopathology

Wood's lamp accentuates the contrast of amelanotic areas and helps to distinguish piebaldism from naevus anaemicus and naevus depigmentosus [18, 21]. Biopsy is unnecessary in most cases and is reserved for doubtful presentations; it should include the full thickness of the epidermis [18]. Depigmented skin has no melanocytes in the epidermis or in the follicles, the hyperpigmented areas have a normal number of melanocytes and, unlike vitiligo, there is no inflammatory infiltrate in the dermis [18]. Comparative immunohistochemistry showed, in the hypomelanotic epidermis of a patient with piebaldism, few melanocytes labelled by TA99 and absence of c-kit protein; in naevus depigmentosus, strong c-kit expression with scarce melanosomes; in vitiligo, absence of all melanocyte markers [93]. Biopsy confirms the absence of melanocytes but does not identify the gene [1, 3].

5.3. Genetic testing: strategy

Molecular testing is not required for the diagnosis of a typical presentation, but it is useful when the presentation is atypical, when café-au-lait macules or freckling raise the possibility of NF1 or Legius syndrome, when there is deafness, heterochromia or intellectual disability, and for reproductive planning [20, 57, 61]. The order proposed by the sources is as follows:

5.4. Yield and limits of the tests

In the series of Ezoe and colleagues, analysed with 1990s methods, KIT variants or deletions were found in 21 of 28 unrelated patients with typical piebaldism (75%), and in 2 of 5 (40%) with an atypical presentation [27]. Later reviews retain the estimate of about 75% of patients with a KIT variant [30, 94]. These values measure the proportion of patients with a variant detected at one point in time and with one technique, not the clinical sensitivity of a current test. A negative result does not exclude the diagnosis, for several reasons: deletions of one or more exons that sequencing does not detect without copy-number analysis [5, 41]; intronic variants outside the canonical positions, such as the insertion NM_000222.3:c.1990+8_1990+9ins18 whose effect was demonstrated only by RT-PCR [53]; balanced chromosomal rearrangements, such as the inversion inv(4)(p16q12) [50]; and the possibility of another gene, such as SNAI2 [12]. In conditions with a mosaic aetiology, the Oxford Desk Reference recommends paired blood and skin samples, with specialist advice on the cell type to analyse [21]; no cases of proven somatic mosaic piebaldism were found in the sources consulted.

5.5. Interpretation and report

The report should state the gene, the transcript with version (NM_000222.3 for KIT), the variant in HGVS nomenclature, zygosity and the class according to the American College of Medical Genetics and Genomics and Association for Molecular Pathology (ACMG/AMP) criteria [2, 34, 94]. Recent studies classify KIT null variants with the PVS1 criterion and absence from population databases (PM2), and splicing variants with minigene assays or RT-PCR [20, 34, 53]. Family segregation is informative, but the incomplete penetrance of the leucoderma, documented in the carrier father without leucoderma in the family with p.Phe584Leu, prevents an untested asymptomatic relative from being considered a non-carrier [10]. A KIT variant found in a tumour (GIST, mastocytosis) should not be interpreted as germline without confirmation in a constitutional sample, and a germline loss-of-function variant does not carry the therapeutic implications of oncogenic variants [1]. A variant of uncertain significance should not be used for prenatal or preimplantation diagnosis.

5.6. Prenatal and preimplantation diagnosis

Prenatal diagnosis is possible when the family variant has been identified [21]. Diagnoses by amniocentesis and by fetal testing in another family have been published, as well as cycles of preimplantation genetic testing for monogenic disease (PGT-M) with haplotype analysis of polymorphisms within a 2-Mb interval on each side of KIT, combined with aneuploidy screening (PGT-A) and confirmation by targeted non-invasive prenatal testing (NIPT-M) [20, 34, 95]. Details are given in section 8.

6. Differential Diagnosis

6.1. Comparative table

Sources for Table 6.1: [1, 10, 17, 18, 21, 33, 34, 46, 61, 68, 80, 93, 96–99].

6.2. Waardenburg syndromes

The Waardenburg syndromes share with piebaldism the white forelock and leucoderma, as they are also defects of neural crest derivatives, but they affect other lineages [10, 61]. The GeneReviews entry for Waardenburg syndrome type I summarises the differential: in piebaldism a white forelock is common, as is absence of pigmentation of the medial forehead and eyebrows and of the chest, abdomen and limbs; hyperpigmented borders around the depigmented areas are characteristic, and heterochromia and sensorineural deafness are rarely described [17]. In Waardenburg syndrome, the white forelock may be present at birth and pigment early, greying is premature and the iris may be heterochromic or brilliant blue, with a hypopigmented fundus [96]. Deafness is the most useful discriminating element: it occurs in 53% in type I, 92% in type II and 84% in type IV, and almost always with SOX10 and MITF variants [96]. Dystopia canthorum (mean family W index of 1.95 or more) separates types I and III from type II [17]. The Brazilian textbook of genetic syndromes includes piebaldism in the differential diagnosis of Waardenburg syndrome, with a triangular area of depigmentation of the midline of the forehead and central scalp and a forelock of white hair [97]. Cases with KIT-related piebaldism and deafness, described as an expanded syndrome, show that the separation is not always clear-cut [29, 30].

6.3. Vitiligo and other acquired leucodermas

Vitiligo is the main source of confusion in adults and older children. It is acquired, progressive, with a symmetrical distribution on the extensor surfaces and periorificial areas, and results from immune-mediated destruction of melanocytes [10, 21]. In segmental vitiligo, which can also be stable, onset is postnatal [22]. Histologically, vitiligo skin may show an inflammatory infiltrate and, on immunohistochemistry, absence of all melanocyte markers, whereas in piebaldism there is no inflammation [18, 93]. The 2025 Japanese vitiligo guideline includes piebaldism and Waardenburg syndrome among the congenital diseases to be distinguished, in a dedicated algorithm for congenital hypopigmentation, and lists as acquired differential diagnoses Vogt–Koyanagi–Harada disease, post-inflammatory hypopigmentation, pityriasis alba, progressive macular hypomelanosis, idiopathic guttate hypomelanosis and infectious leucodermas [100]. A 2026 review of vitiligo mimics in childhood summarises the differences: in piebaldism the patches do not expand and there are no auditory or ocular changes [80].

6.4. Café-au-lait macules: NF1 and Legius syndrome

The frequency of café-au-lait macules and freckling in piebaldism leads to misdiagnoses of NF1 [10, 76]. Oiso and colleagues argue that coexistence of NF1 should be accepted only with neurofibromas or a demonstrated NF1 variant, because more than six café-au-lait macules and axillary freckling may occur in piebaldism [10]. Akarsu and colleagues suggest testing KIT and SPRED1 in these patients [101]. Combined testing of KIT, NF1 and SPRED1 resolves the diagnosis in most published cases [57, 71, 72].

6.5. Other entities

Naevus depigmentosus is a congenital hypopigmented macule with a serrated and irregular border, solitary, segmental or systematised, which changes little after birth [10]. Pigmentary mosaicism of the hypopigmented type follows Blaschko lines and is frequently associated with neurological defects; a mosaic chromosomal aetiology has been demonstrated in about 60% of reported cases [10, 21]. Solitary lesions similar to the macules of tuberous sclerosis occur in 6% of children and 4% of adults under 45 years without the disease, but fewer than 1% have several and no person without tuberous sclerosis has more than three [21]. The white forelock with malformations syndrome (OMIM 277740; ORPHA:2475) was described by Goodman and colleagues in 1980 in two Ashkenazi Jewish siblings with poliosis, characteristic facies, hypertelorism, atrial septal defect, prominent thoracic and abdominal veins, hypoplasia of the distal phalanges of the toes and segmental bronchomalacia [7, 102]. Oculocutaneous albinism, including the syndromic forms of Hermansky–Pudlak, Chediak–Higashi and Griscelli, is generalised and not patchy [10, 80]. In BAP1 tumour predisposition syndrome, Njauw and colleagues described in 2026 a patient with a white forelock from birth, without ocular or auditory changes, who developed melanoma at 49 years and breast cancer at 52; of the 13 additional carriers examined under Wood's light, 7 had chronic poliosis or depigmentation, and the mouse with melanocyte-specific Bap1 deletion had depigmented paws and a white abdominal spot in 3 of 4 animals [46]. The series is small, but it indicates that a familial white forelock with tumours in the family should not be attributed automatically to piebaldism [46].

7. Treatments and Risk Management Strategies

7.1. Principles

Piebaldism is benign and stable, but its cosmetic impact can cause social and psychological disability [18, 103]. Treatment addresses appearance and protection of the depigmented skin; there is no pharmacological therapy, topical or systemic, that restores absent melanocytes [1, 18, 70]. The depigmented areas of piebaldism do not respond to medical treatment or to phototherapy alone, unlike non-segmental vitiligo, because the follicular melanocytes that serve as a reservoir for repigmentation are also missing [22, 104]. A 2025 review of topical treatments in rare genodermatoses found no report or trial of a specific topical therapy for piebaldism [70]. There is no guideline dedicated to piebaldism; the available surgical recommendations were written for stable vitiligo and are applied by analogy, and the 2021 British vitiligo guideline expressly excludes piebaldism from its scope [98].

7.2. Photoprotection

The absence of epidermal melanin makes depigmented skin more sensitive to ultraviolet radiation; patients should be educated about sun protection of the depigmented areas, with sunscreen and clothing [18, 69]. For vitiligo, the British guideline recommends sunscreen with sun protection factor (SPF) 50 and a 4- or 5-star UVA rating, applied to the patches and surrounding skin before exposure (good practice), and the German guideline recommends SPF of 50 or more [98, 105]. Reviews report an increased risk of sunburn and skin cancer in areas without melanocytes, without quantification in the sources consulted [70, 80].

7.3. Camouflage and psychological support

Camouflage make-up and hair colouring for the poliosis improve quality of life, although the effect is temporary [18, 56]. The German vitiligo guideline describes creams, sprays, liquid or compact foundations, concealers and setting sprays, and self-tanners with an effect lasting 3 to 5 days [105]. The 2025 Japanese guideline gives camouflage grade 1B and considers dihydroxyacetone self-tanners safe for camouflaging segmental vitiligo or leucoderma until surgery is possible, citing a described application to piebaldism lesions [100]. The British guideline recommends considering a camouflage consultation (weak recommendation), offering self-help information for mild psychological distress and referring for cognitive behavioural therapy for moderate to severe distress (strong recommendations) [98]. StatPearls suggests referral to mental health services when there is social disability [18].

7.4. Surgical treatment: autologous melanocyte transplantation

Autologous melanocyte transplantation from normally pigmented skin is the only treatment that durably repigments the patches of piebaldism [10, 18, 103]. The techniques are divided into tissue grafts (punch grafts or minigrafts, suction blister epidermal grafts, thin or ultrathin split-thickness skin grafts) and cellular grafts (non-cultured epidermal cell suspension, also called melanocyte–keratinocyte transplantation, and cultured melanocyte or epidermis transplantation) [100, 103, 105]. Piebaldism and segmental vitiligo share a stable course without persistent autoimmunity against melanocytes, which makes them the best candidates for these techniques [22, 106].

Table 7.1 summarises the studies including patients with piebaldism.

None of these studies compares techniques exclusively in patients with piebaldism with sufficient size for strong conclusions; the results come mainly from case series and small trials that mix piebaldism and vitiligo [103]. A 2024 Chinese retrospective study comparing cultured epidermis and non-cultured suspension in nine patients with piebaldism was retracted in 2025 and should not be used as evidence [113, 114].

7.5. Recipient-bed preparation trial

In the trial by Lommerts and colleagues (Amsterdam, May 2015 to February 2016; NCT02458417), each patient received, on four randomly allocated 4-cm² patches of the trunk or limbs, full-surface ablation with carbon dioxide (CO2) laser at about 209 µm, at about 144 µm, fractional ablation, or no treatment (control) [22]. The cell suspension was prepared from about 4 cm² of split-thickness skin from the hip harvested with an electric dermatome at a depth of 0.2 mm, with a donor-to-recipient ratio of 1:4 to 1:5 [22]. At six months, median repigmentation was 68.7% (interquartile range, IQR, 12.7–100) with 209 µm and 58.3% (14.3–100.1) with 144 µm, both higher than control (0%), and 0% with fractional ablation; more than 75% repigmentation occurred in 50% and 40% of the sites treated with full-surface ablation [22]. Mild to moderate persistent erythema was more frequent with 209 µm (70%) than with 144 µm (50%), there was mild hyperpigmentation in 10% of sites and hypertrophic donor-site scarring in two patients [22]. The authors recommend full-surface ablation at about 144 µm. Patients with phototype I, recurrent herpes simplex, hypertrophic scars or keloids, pregnancy or breastfeeding and a history of skin cancer were excluded [22].

The trial has ten patients, mixes two diseases and did not measure maintenance of repigmentation; the differences between 209 and 144 µm were not significant (p=0.89) [22].

7.6. Expansion ratio and choice of technique

The systematic review by Narayan and colleagues included 31 studies with 1591 patients and 3081 lesions of vitiligo and piebaldism [103]. Donor-to-recipient ratios ranged from 1:1 to 1:10 with non-cultured suspension and from 1:20 to 1:100 with cultured melanocytes; with non-cultured suspension, a ratio of 1:3 achieved more lesions with repigmentation above 50% and 75% than a ratio of 1:10, and the studies comparing non-cultured suspension with culture showed no differences [103]. Culture requires time, a sterile laboratory and trained staff, and is more expensive [103]; the 2025 Indian consensus states that the culture cycle takes about 21 days and that most experts attribute a theoretical carcinogenic potential to it [115]. The 2025 Japanese guideline reports that the cultured autologous epidermal sheet with melanocytes has been approved in Japan for patients over 12 years and that cell suspension and cultured melanocytes are subject to the Japanese regenerative medicine law [100]. Table 7.2 compares the techniques.

7.7. Vitiligo guideline recommendations applied by analogy

In piebaldism, the stability requirement is met from the outset, because the leucoderma is congenital and stable; the exceptions with spontaneous progression or regression (section 3.5) justify an observation period before surgery in young children, which the sources consulted do not quantify [55, 56].

7.8. Perioperative care described in the trials

In the Lommerts trial, anaesthesia was local with 2% lidocaine, the sites were covered with a non-adherent dressing and paraffin gauze for seven days, clarithromycin 500 mg once daily for seven days was recommended and, to make repigmentation visible, UVA exposure twice weekly with a facial tanning device between the fourth week and the sixth month [22]. Njoo and colleagues used UVA 10 J/cm² after grafting to stimulate melanocyte migration [104]. The Indian consensus mentions postoperative adjuvants (topical tacrolimus, with or without phototherapy, and excimer light) used in vitiligo, whose usefulness in piebaldism has not been studied [115]. These schedules are study protocols and not reference doses for the condition.

7.9. Registered clinical trials

There are no trials of drugs, gene therapy or cell therapies specific to piebaldism registered on ClinicalTrials.gov at the date of consultation [116]. The absence of registrations does not prove that no research exists.

7.10. Developments in the last 12 months

Between October 2025 and October 2026 there were no authorisations, regulatory opinions or pharmacological trials for piebaldism in the sources consulted [116]. The published developments concern diagnosis and reproduction: the combined application of PGT-M, PGT-A and NIPT-M in families with KIT variants (published study) [34], the demonstration by RT-PCR of an intronic splicing variant outside the canonical positions (published study) [53], the second edition of the Japanese vitiligo guidelines, with piebaldism in the congenital hypopigmentation algorithm and the Japanese approval of the cultured epidermal sheet for those over 12 years (guideline) [100], the description of poliosis and depigmentation in carriers of germline BAP1 variants (published case series) [46] and a letter on complete repigmentation with non-cultured epidermal suspension (report) [119]. The retraction, in 2025, of a comparative study of surgical techniques in piebaldism alters the available evidence base [114].

7.11. Pregnancy, children and special situations

Piebaldism has no implications for pregnancy beyond reproductive counselling; elective surgery was excluded in pregnancy and breastfeeding in the Lommerts trial [22]. In children, the Indian consensus limits surgery before 10 years to cosmetically sensitive areas and to patient cooperation, and the Japanese guideline reports approval of cultured epidermis only above 12 years [100, 115]. Children with piebaldism and café-au-lait macules should have their molecular diagnosis clarified before being enrolled in NF1 surveillance programmes [57, 101].

8. Reproductive Options and Family Counselling

8.1. Recurrence risk

Piebaldism is autosomal dominant: each child of an affected person has a 50% chance of inheriting the variant, regardless of sex [9, 21]. Most patients have a family history, with families of four to six generations described [20, 36, 48, 120], but there are de novo variants, as in the case described in section 10, in which the variant was absent from the parents and from the unaffected twin [57, 121]. When both parents are affected, there is a 25% chance of homozygosity, with a more severe phenotype that may include deafness and developmental delay [11, 31]. In larger 4q12 deletions, the risk depends on whether the deletion is de novo or inherited and on the genes included [5, 33].

8.2. Expressivity and penetrance in counselling

Severity in a child cannot be predicted accurately from that of the parent. Kinase-domain variants tend to produce a severe phenotype and null or extracellular variants a mild phenotype, but the same variant can give different phenotypes in the same family, and a carrier may have no leucoderma [10, 20, 62]. In the family with p.Phe584Leu, the carrier father had only café-au-lait macules and the children mild to moderate piebaldism [10]. Testing of at-risk relatives should therefore be molecular when the family variant is known, and not only clinical.

8.3. Prenatal diagnosis

Prenatal diagnosis requires the family variant to have been identified [21]. In a Chinese series, a 26-year-old man with severe piebaldism and the c.1747G>A variant requested prenatal diagnosis at 16 weeks of his wife's pregnancy; amniocentesis confirmed that the fetus had inherited the variant and the couple decided to continue the pregnancy after counselling, preferring preimplantation diagnosis in the next pregnancy [20]. In another Chinese family with the variant NM_000222.3:c.2326G>A p.(Val776Met), prenatal testing showed the same genotype in the fetus [95]. Discussion of prenatal diagnosis in a benign, stable condition without systemic manifestations should respect the couple's autonomy; in the published series, families mainly valued the possibility of interrupting transmission through preimplantation diagnosis [20].

8.4. Preimplantation genetic testing

Zhang and colleagues reported that the four families in their series expressed a preference for preimplantation genetic testing [20]. Zhou and colleagues published in 2026 the first combined application of PGT-M, PGT-A and NIPT-M in KIT-associated pigmentary disorders [34]. PGT-M used next-generation sequencing of polymorphisms located up to 2 Mb upstream and downstream of the variant, with samples from the couple and their parents, to reduce the risk of allele dropout and contamination; PGT-A excluded aneuploid embryos [34]. In a family with classic piebaldism and the variant NM_000222.3:c.2736_2737insT p.(Lys913Ter), nine blastocysts were tested and transfer of one euploid non-carrier embryo resulted in the birth of a healthy child at 39 weeks; in another family, with NM_000222.3:c.2664del p.(Met889Cysfs*14), 16 blastocysts were tested and the pregnancy was terminated at 23 weeks for amniotic band syndrome, unrelated to the disease, and it was confirmed that the fetus did not carry the variant [34]. In the third family, with a gain-of-function variant, NIPT-M at 13 weeks (fetal fraction of 14.5%, analytical sensitivity of 98.7% for the normal paternal haplotype) confirmed the PGT result [34]. The authors stress that NIPT-M is a screening test and is not equivalent to invasive diagnosis, and that variants of maternal origin are harder to analyse in maternal plasma [34].

8.5. Testing of minors and relatives

The sources consulted contain no specific recommendations on predictive testing of minors in piebaldism. As the condition manifests at birth, the diagnosis of an affected child is usually clinical, and molecular testing of a minor is mainly useful when the presentation is atypical or when there are café-au-lait macules that raise the possibility of NF1 [57, 101]. The distinction between loss-of-function variants (piebaldism) and gain-of-function variants (familial GIST and hyperpigmentation) has opposite consequences for the surveillance of relatives: only the latter warrant gastrointestinal surveillance [1, 34].

9. Special Considerations: Population Diversity and Epidemiology

9.1. Prevalence

Orphanet classifies the prevalence of piebaldism as unknown, with no validated estimate [9]. The incidence of "less than 1 in 20,000" is repeated by StatPearls, by reviews and by case series, with no sex predominance or ethnic predilection [18, 20, 69]. StatPearls attributes this figure to a 2012 Indian review that was retracted in 2024; no population study supporting it was found in the sources consulted [18, 19, 122]. There are no prevalence data for Portugal or Brazil in the sources consulted.

9.2. Geographical distribution of the published series

Piebaldism has been described in populations on several continents. The first variant was identified in an Ashkenazi Jewish family [25, 57]; there followed a family with seven affected individuals in three generations without other stigmata, a South African Xhosa patient with deafness [29, 38], a large Italian family with a 12-base-pair deletion [51], Japanese families that showed incomplete penetrance and the modifying role of MC1R [10, 60, 123], an Indian family with a mild phenotype [59], a Tunisian family [124], Saudi families [30, 56], an Inuit infant with a piebaldism–Waardenburg presentation [40], children from Senegal including twins [125] and numerous Chinese families, from which the main recent genotype–phenotype reviews come [20, 34, 48, 94, 120]. In patients of mixed ancestry, phenotypes with café-au-lait macules and freckling meeting the clinical criteria for NF1 have been described more frequently [57, 71]. From Brazil, the literature consulted includes a report of melanocyte transplantation in piebaldism and the chapter of the Brazilian textbook of genetic syndromes that includes piebaldism in the differential diagnosis of Waardenburg syndrome [97, 126]. No founder variants have been identified.

9.3. Phototype and special populations

In the melanocyte–keratinocyte transplantation cohort of Maghfour and colleagues, 55% of patients had phototypes IV to VI [112]; in the van Geel series, 80% of patients reported some colour mismatch after grafting, less noticeable after sun exposure [106]. Phototype I was an exclusion criterion in the Lommerts trial [22].

9.4. Reference networks and patient resources

In the European Union, patients with piebaldism fall within ERN-Skin, the European reference network for rare skin diseases, organised into nine thematic groups [24]. The Orphanet entry (ORPHA:2884) is the starting point for locating resources by country [9]. No patient organisation dedicated to piebaldism was identified in the sources consulted.

10. Illustrative Clinical Case

Nagaputra and colleagues published in 2018 the case of a girl with piebaldism, café-au-lait-like macules and inguinal freckling, caused by a de novo KIT variant [57]. The patient was one of dichorionic diamniotic twins conceived by in vitro fertilisation by a non-consanguineous couple of German and Chinese ancestry, born in Germany at 33 weeks by emergency caesarean section, with Apgar scores of 9 at the first and fifth minutes. At birth, she had a white forelock, depigmented patches and hyperpigmented lesions similar to café-au-lait macules; cranial ultrasound and audiological assessment were normal and NF1 testing was negative [57].

She was first seen in Singapore at 4 years and 5 months. She had a whitish-blonde forelock and a well-demarcated hypopigmented patch from the central forehead to the glabella, nasal bridge and both cheeks, sparing the columella and chin; hypopigmented or depigmented patches with islands of normal skin on the anterior neck, on the ventral aspect of the upper limbs (from the proximal arm to the distal forearm) and on the ventral aspect of the lower limbs (from the proximal thigh to the distal leg); multiple hyperpigmented lesions, some larger than 1 cm, mainly on the lower limbs and back; and freckling in the inguinal folds. She had no neurofibromas, heterochromia, Lisch nodules or optic glioma, development was age-appropriate and there was no family history of pigmentary disease [57]. Figure 1 of the article (https://pmc.ncbi.nlm.nih.gov/articles/PMC5911795/figure/fig1/) shows the forehead patch and the limb patches with islands of normal skin.

Sequencing with a clinical exome panel found no pathogenic variants in NF1 or SPRED1 and identified the heterozygous variant NM_000222.2:c.2000T>G in KIT, predicting the substitution p.(Leu667Arg) in the first tyrosine kinase domain [57]. The variant, confirmed by Sanger sequencing, was absent from the unaffected twin and the parents (Figure 2: https://pmc.ncbi.nlm.nih.gov/articles/PMC5911795/figure/fig2/), and was not listed in ClinVar or in the Human Gene Mutation Database (HGMD) at the time [57]. In current nomenclature, it corresponds to NM_000222.3:c.2000T>G p.(Leu667Arg), classified as likely pathogenic in ClinVar (VCV000393590) [2, 54]. The authors interpreted the café-au-lait macules as part of the spectrum of piebaldism associated with kinase-domain variants, stressed that the molecular diagnosis excluded NF1 and Legius syndrome and is relevant for tumour surveillance, because gliomas are described in NF1 and stromal tumours with KIT variants, and noted that the patient is the third person of mixed ancestry described with this phenotype [57].

The case illustrates four points: the de novo variant explains the absence of a family history; the overlap with NF1 is real and only combined KIT/NF1/SPRED1 testing resolves it; the location of the variant in the kinase domain agrees with the correlation between kinase domain, severe phenotype and café-au-lait macules described in the case reviews [20, 48]; and the recurrence risk for siblings is low, whereas that for the patient's offspring is 50%.

11. Prognosis and Long-Term Follow-up

11.1. Prognosis

Isolated piebaldism is benign, does not progress in most patients and does not reduce life expectancy [3, 18, 61]. Prognosis depends mainly on the psychosocial impact, described as stigmatising and with loss of quality of life [18, 103]. The exceptions to stability include progression of depigmentation (NM_000222.3:c.1859T>C p.(Val620Ala)) and partial spontaneous regression (section 3.5) [55, 56]. After autologous transplantation, the repigmentation obtained in piebaldism is maintained at follow-up: in the van Geel series, loss of repigmentation during a mean follow-up of 4 years (up to 7.7 years) occurred only in patients with generalised vitiligo, and final repigmentation was reached on average at 10 months [106]; repigmentation with cultured epidermis has been described as permanent [23]. The forms with deafness, homozygosity or 4q12 deletion have the prognosis of the associated manifestations [29, 31, 33].

11.2. Surveillance

There are no published surveillance protocols for piebaldism. The following table brings together the recommendations of the sources consulted, with their respective origin.

StatPearls recommends an interprofessional team including dermatology, paediatrics, gastroenterology and genetics, especially to exclude syndromic forms at birth, and reassurance of the family about the benign and non-progressive nature of the condition [18].

12. Summary and Final Considerations

Piebaldism is an autosomal dominant disorder of melanocyte development in which migration and survival of melanoblasts fail in the ventral and midline regions, leaving from birth a frontal white forelock and sharply demarcated patches of leucoderma on the forehead, anterior trunk and mid-portion of the limbs, without melanocytes and with hyperpigmented islands. The great majority of cases are due to KIT loss-of-function variants, and severity correlates with mechanism: null and extracellular variants cause haploinsufficiency and a mild phenotype, whereas missense variants in the kinase domains act as dominant negatives and cause a severe phenotype, frequently with café-au-lait macules. Penetrance of the leucoderma may be incomplete and intrafamilial variability is real, which limits clinical prediction in counselling. The contribution of SNAI2 rests on a few deletion cases and remains debated.

The diagnosis is clinical, supported by Wood's lamp and, in atypical cases, by biopsy; molecular testing of KIT with copy-number analysis confirms the diagnosis in about three-quarters of typical cases and is indispensable when café-au-lait macules mimic NF1 or Legius syndrome, when there is deafness, heterochromia or intellectual disability, and for reproductive planning. The main differential diagnosis is with the Waardenburg syndromes, through auditory and ocular examination and dystopia canthorum, and with vitiligo, through its acquired and progressive nature; a congenital white forelock in families with melanoma should raise consideration of BAP1 syndrome.

There is no pharmacological treatment. Management rests on photoprotection, camouflage, psychological support and, for those who wish it, autologous melanocyte transplantation, with 90–100% repigmentation in series of split-thickness skin grafts and cultured epidermis and with durable results after non-cultured cell suspension; the surgical recommendations are derived from the guidelines for stable vitiligo. Reproductive options include prenatal diagnosis and preimplantation genetic testing, already applied successfully in families with KIT variants. The true prevalence remains unknown, and the estimate usually cited has no population basis.

13. References

1. GeneGuidance. KIT — clinical gene curation (GeneGuidance database, version of 2026-09-26). [accessed 2026-10-29].
2. Freeman PJ, Hart RK, Gretton LJ, Brookes AJ, Dalgleish R. VariantValidator: accurate validation, mapping, and formatting of sequence variation descriptions. Hum Mutat. 2018;39(1):61-68. doi:10.1002/humu.23348. PMID: 28967166.
3. GeneGuidance. SNAI2 — clinical gene curation. [accessed 2026-10-29].
4. Spritz RA, Droetto S, Fukushima Y. Deletion of the KIT and PDGFRA genes in a patient with piebaldism. Am J Med Genet. 1992;44(4):492-495. doi:10.1002/ajmg.1320440422. PMID: 1279971.
5. Arasimavičius J, Dilytė E, Utkus A, Preikšaitienė E. A Familial 4q12 Deletion Involving KIT Gene Causes Piebaldism. Acta Dermatovenerol Croat. 2020;28(2):105-108. PMID: 32876036.
6. Orphanet. Piebald trait-neurologic defects syndrome (ORPHA:2885). [accessed 2026-10-29]. https://www.orpha.net/en/disease/detail/2885
7. Orphanet. White forelock with malformations (ORPHA:2475). [accessed 2026-10-29]. https://www.orpha.net/en/disease/detail/2475
8. Orphanet. Osteopathia striata-pigmentary dermopathy-white forelock syndrome (ORPHA:2779). [accessed 2026-10-29]. https://www.orpha.net/en/disease/detail/2779
9. Orphanet. Piebaldism (ORPHA:2884). Paris: INSERM; [accessed 2026-10-29]. Available from: https://www.orpha.net/en/disease/detail/2884
10. Oiso N, Fukai K, Kawada A, Suzuki T. Piebaldism. J Dermatol. 2013;40(5):330-335. doi:10.1111/j.1346-8138.2012.01583.x. PMID: 22670867.
11. Hultén MA, Honeyman MM, Mayne AJ, Tarlow MJ. Homozygosity in piebald trait. J Med Genet. 1987;24(9):568-571. doi:10.1136/jmg.24.9.568. PMID: 3669051. PMC1050271.
12. Sánchez-Martín M, Pérez-Losada J, Rodríguez-García A, González-Sánchez B, Korf BR, Kuster W, et al. Deletion of the SLUG (SNAI2) gene results in human piebaldism. Am J Med Genet A. 2003;122A(2):125-132. doi:10.1002/ajmg.a.20345. PMID: 12955764.
13. Telfer MA, Sugar M, Jaeger EA, Mulcahy J. Dominant piebald trait (white forelock and leukoderma) with neurological impairment. Am J Hum Genet. 1971;23(4):383-389. PMID: 5097904. PMC1706704.
14. Online Mendelian Inheritance in Man, OMIM®. #172800 Piebaldism. Baltimore (MD): Johns Hopkins University; [accessed 2026-10-29]. Available from: https://omim.org/entry/172800
15. Online Mendelian Inheritance in Man, OMIM®. *164920 KIT proto-oncogene, receptor tyrosine kinase; KIT. Baltimore (MD): Johns Hopkins University; [accessed 2026-10-29]. Available from: https://omim.org/entry/164920
16. Online Mendelian Inheritance in Man, OMIM®. 172850 Piebald trait with neurologic defects. Baltimore (MD): Johns Hopkins University; [accessed 2026-10-29]. Available from: https://omim.org/entry/172850
17. Milunsky JM. Waardenburg Syndrome Type I. 2001 Jul 30 [updated 2022 Oct 20]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1531/
18. Shah M, Patton E, Zedek D. Piebaldism. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; [updated 2023; accessed 2026-10-29]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544238/ PMID: 31334958.
19. Retraction: Piebaldism: A Brief Report and Review of the Literature. Indian Dermatol Online J. 2024;15(3):569. doi:10.4103/idoj.idoj_305_24. PMID: 38845665. PMC11152498.
20. Zhang Y, Gao H, Zhang L, Zhao Y, Qiu C, Liu X. Novel Germline KIT Variants in Families With Severe Piebaldism: Case Series and Literature Review. J Clin Lab Anal. 2024;38(11-12):e25073. doi:10.1002/jcla.25073. PMID: 38887855. PMC11252829.
21. Firth HV, Hurst JA. Oxford Desk Reference: Clinical Genetics and Genomics. 2nd ed. Oxford: Oxford University Press; 2017. Patchy hypo- or depigmented skin lesions; p. 276–277.
22. Lommerts JE, Meesters AA, Komen L, Bekkenk MW, de Rie MA, Luiten RM, et al. Autologous cell suspension grafting in segmental vitiligo and piebaldism: a randomized controlled trial comparing full surface and fractional CO2 laser recipient-site preparations. Br J Dermatol. 2017;177(5):1293-1298. doi:10.1111/bjd.15569. PMID: 28403523.
23. Guerra L, Primavera G, Raskovic D, Pellegrini G, Golisano O, Bondanza S, et al. Permanent repigmentation of piebaldism by erbium:YAG laser and autologous cultured epidermis. Br J Dermatol. 2004;150(4):715-721. doi:10.1111/j.0007-0963.2004.05500.x. PMID: 15099368.
24. ERN-Skin. European Reference Network for rare and complex diseases of the skin [Internet]. Paris: ERN-Skin; [accessed 2026-10-29]. Available from: https://ern-skin.eu/
25. Giebel LB, Spritz RA. Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Proc Natl Acad Sci U S A. 1991;88(19):8696-8699. doi:10.1073/pnas.88.19.8696. PMID: 1717985. PMC52576.
26. Spritz RA, Giebel LB, Holmes SA. Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. Am J Hum Genet. 1992;50(2):261-269. PMID: 1370874. PMC1682440.
27. Ezoe K, Holmes SA, Ho L, Bennett CP, Bolognia JL, Brueton L, et al. Novel mutations and deletions of the KIT (steel factor receptor) gene in human piebaldism. Am J Hum Genet. 1995;56(1):58-66. PMID: 7529964. PMC1801299.
28. Mirhadi S, Spritz RA, Moss C. Does SNAI2 mutation cause human piebaldism and Waardenburg syndrome?. Am J Med Genet A. 2020;182(12):3074-3075. doi:10.1002/ajmg.a.61887. PMID: 32975012.
29. Spritz RA, Beighton P. Piebaldism with deafness: molecular evidence for an expanded syndrome. Am J Med Genet. 1998;75(1):101-103. doi:10.1002/(sici)1096-8628(19980106)75:1<101::aid-ajmg20>3.0.co;2-p. PMID: 9450866.
30. Hamadah I, Chisti M, Haider M, Al Dosssari H, Alhumaidan R, Meyer BF, et al. A novel KIT mutation in a family with expanded syndrome of piebaldism. JAAD Case Rep. 2019;5(7):627-631. doi:10.1016/j.jdcr.2019.01.021. PMID: 31341943. PMC6630042.
31. Kilsby AJ, Cruwys M, Kukendrajah C, Russell-Eggitt I, Raglan E, Rajput K, et al. Homozygosity for piebaldism with a proven KIT mutation resulting in depigmentation of the skin and hair, deafness, developmental delay and autism spectrum disorder. Clin Dysmorphol. 2013;22(2):64-67. doi:10.1097/mcd.0b013e32835e8ce5. PMID: 23399981.
32. Hoo JJ, Haslam RH, van Orman C. Tentative assignment of piebald trait gene to chromosome band 4q12. Hum Genet. 1986;73(3):230-231. doi:10.1007/bf00401233. PMID: 3733079.
33. Hemati P, du Souich C, Boerkoel CF. 4q12-4q21.21 deletion genotype-phenotype correlation and the absence of piebaldism in presence of KIT haploinsufficiency. Am J Med Genet A. 2015;167A(1):231-237. doi:10.1002/ajmg.a.36821. PMID: 25355368.
34. Zhou Z, Liang S, Qin N, Yang J, Tian M, Teng X, et al. Preimplantation genetic testing for KIT-associated pigmentary monogenic diseases. Front Med (Lausanne). 2026;13:1947434. doi:10.3389/fmed.2026.1947434. PMID: 42889262.
35. FROGGATT P. An outline, with bibliography, of human piebaldism and white forelock. Ir J Med Sci. 1959(398):86-94. doi:10.1007/bf02954762. PMID: 13640782.
36. Pierard GE, Franchimont C, Lapière M. Six generations of piebaldism. Dermatologica. 1979;158(3):184. PMID: 446823.
37. Bankier A, Sheffield L. Piebaldism, an autosomal dominant trait distinct from Waardenburg syndrome. Am J Med Genet. 1990;37(4):600-602. doi:10.1002/ajmg.1320370435. PMID: 2260612.
38. Winship I, Young K, Martell R, Ramesar R, Curtis D, Beighton P. Piebaldism: an autonomous autosomal dominant entity. Clin Genet. 1991;39(5):330-337. doi:10.1111/j.1399-0004.1991.tb03039.x. PMID: 1860249.
39. Ortonne JP. Piebaldism, Waardenburg's syndrome, and related disorders. "Neural crest depigmentation syndromes"?. Dermatol Clin. 1988;6(2):205-216. doi:10.1016/s0733-8635(18)30667-3. PMID: 3288381.
40. Kaplan P, de Chaderévian JP. Piebaldism-Waardenburg syndrome: histopathologic evidence for a neural crest syndrome. Am J Med Genet. 1988;31(3):679-688. doi:10.1002/ajmg.1320310324. PMID: 3228147.
41. Fleischman RA, Saltman DL, Stastny V, Zneimer S. Deletion of the c-kit protooncogene in the human developmental defect piebald trait. Proc Natl Acad Sci U S A. 1991;88(23):10885-10889. doi:10.1073/pnas.88.23.10885. PMID: 1720553. PMC53036.
42. Fleischman RA. Human piebald trait resulting from a dominant negative mutant allele of the c-kit membrane receptor gene. J Clin Invest. 1992;89(6):1713-1717. doi:10.1172/jci115772. PMID: 1376329. PMC295855.
43. Spritz RA, Holmes SA, Ramesar R, Greenberg J, Curtis D, Beighton P. Mutations of the KIT (mast/stem cell growth factor receptor) proto-oncogene account for a continuous range of phenotypes in human piebaldism. Am J Hum Genet. 1992;51(5):1058-1065. PMID: 1384325. PMC1682829.
44. Sánchez-Martín M, Rodríguez-García A, Pérez-Losada J, Sagrera A, Read AP, Sánchez-García I. SLUG (SNAI2) deletions in patients with Waardenburg disease. Hum Mol Genet. 2002;11(25):3231-3236. doi:10.1093/hmg/11.25.3231. PMID: 12444107.
45. Iamsumang W, Kositkuljorn C, Leerunyakul K, Sakpuwadol N, Tejapira K, Suchonwanit P. Leukotrichia: A comprehensive review of follicular depigmentation. J Int Med Res. 2026;54(9):3000605261483177. doi:10.1177/03000605261483177. PMID: 42675998. PMC13535012.
46. Njauw CN, Ji Z, Latoni DI, Villa-Gonzalez JM, McCormick S, Kumar R, et al. Germline inactivation of tumor suppressor BAP1 is associated with white spotting. J Clin Invest. 2026;136(1):e195809. doi:10.1172/jci195809. PMID: 41480773. PMC12721880.
47. Funkhouser CH, Kinsler VA, Frieden IJ. Striking contiguous depigmentation across the lower limbs in piebaldism and its implications for understanding melanocytic migration and development. Pediatr Dermatol. 2019;36(4):511-513. doi:10.1111/pde.13831. PMID: 30983016.
48. Li X, Xing X, Liang X, Song C, Yang J, Ren D, et al. Piebaldism with café-au-lait macules resulting from a novel mutation of KIT gene in a three-generation Chinese family. Skin Res Technol. 2023;29(6):e13352. doi:10.1111/srt.13352. PMID: 37357653. PMC10209842.
49. Hattori M, Ishikawa O, Oikawa D, Amano H, Yasuda M, Kaira K, et al. In-frame Val216-Ser217 deletion of KIT in mild piebaldism causes aberrant secretion and SCF response. J Dermatol Sci. 2018;91(1):35-42. doi:10.1016/j.jdermsci.2018.03.012. PMID: 29631773.
50. Ramadevi AR, Naik U, Dutta U, Srikanth , Prabhakara K. De novo pericentric inversion of chromosome 4, inv(4)(p16q12) in a boy with piebaldism and mental retardation. Am J Med Genet. 2002;113(2):190-192. doi:10.1002/ajmg.10739. PMID: 12407711.
51. Riva P, Milani N, Gandolfi P, Larizza L. A 12-bp deletion (7818del12) in the c-kit protooncogene in a large Italian kindred with piebaldism. Hum Mutat. 1995;6(4):343-345. doi:10.1002/humu.1380060409. PMID: 8680409.
52. Spritz RA, Holmes SA, Berg SZ, Nordlund JJ, Fukai K. A recurrent deletion in the KIT (mast/stem cell growth factor receptor) proto-oncogene is a frequent cause of human piebaldism. Hum Mol Genet. 1993;2(9):1499-1500. doi:10.1093/hmg/2.9.1499. PMID: 7694728.
53. Yan K, Wang L, Pan J, Huang H, Dong M. [Genetic and functional characterization of a novel KIT splicing variant in a Chinese three-generation pedigree with piebaldism]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2026:1-7. doi:10.3724/zdxbyxb-2026-0448. PMID: 42703759.
54. National Center for Biotechnology Information. ClinVar: KIT[gene] AND piebaldism [Internet]. Bethesda (MD): NCBI; [accessed 2026-10-29]. Available from: https://www.ncbi.nlm.nih.gov/clinvar/?term=KIT%5Bgene%5D+AND+piebaldism
55. Richards KA, Fukai K, Oiso N, Paller AS. A novel KIT mutation results in piebaldism with progressive depigmentation. J Am Acad Dermatol. 2001;44(2):288-292. doi:10.1067/mjd.2001.112221. PMID: 11174389.
56. Budair FM. KIT Mutation Associated with Depigmented Patches Regression and Multiple Café-au-lait Macules Development in a Patient with Piebaldism: A Case Report. Clin Cosmet Investig Dermatol. 2024;17:713-716. doi:10.2147/ccid.s449691. PMID: 38524391. PMC10961011.
57. Nagaputra JC, Koh MJA, Brett M, Lim ECP, Lim HW, Tan EC. Piebaldism with multiple café-au-lait-like hyperpigmented macules and inguinal freckling caused by a novel KIT mutation. JAAD Case Rep. 2018;4(4):318-321. doi:10.1016/j.jdcr.2017.10.005. PMID: 29693058. PMC5911795.
58. Fleischman RA, Gallardo T, Mi X. Mutations in the ligand-binding domain of the kit receptor: an uncommon site in human piebaldism. J Invest Dermatol. 1996;107(5):703-706. doi:10.1111/1523-1747.ep12365596. PMID: 8875953.
59. Chong KL, Common JE, Lane EB, Goh BK. A novel mutation in the kinase domain of KIT in an Indian family with a mild piebaldism phenotype. J Dermatol Sci. 2010;59(3):206-209. doi:10.1016/j.jdermsci.2010.06.009. PMID: 20688482.
60. Narita T, Oiso N, Fukai K, Motokawa T, Hayashi M, Yokoyama K, et al. Two children with a mild or moderate piebaldism phenotype and a father without leukoderma in a family with the same recurrent missense mutation in the kinase domain of KIT. Eur J Dermatol. 2011;21(3):446-447. doi:10.1684/ejd.2011.1350. PMID: 21680281.
61. Okamura K, Suzuki T. Genetic Pigmentary Disorders: From Molecular Mechanisms to Clinical Manifestations. J Dermatol. 2026;53(2):169-179. doi:10.1111/1346-8138.70024. PMID: 41127964. PMC12877986.
62. Yang B, Yang Q, Yan H, Sun T, Wu N. A novel KIT frame-shift mutation in a large Chinese family with variably severe phenotypes of piebaldism. J Dermatol. 2013;40(2):126-127. doi:10.1111/1346-8138.12007. PMID: 23083126.
63. Yang YJ, Zhao R, He XY, Li LP, Chen W, Wang KW, et al. SNAI2 mutation causes human piebaldism. Am J Med Genet A. 2014;164A(3):855-857. doi:10.1002/ajmg.a.36332. PMID: 24443330.
64. Online Mendelian Inheritance in Man, OMIM®. *602150 Snail family transcriptional repressor 2; SNAI2. Baltimore (MD): Johns Hopkins University; [accessed 2026-10-29]. Available from: https://omim.org/entry/602150
65. Nishida T, Hirota S, Taniguchi M, Hashimoto K, Isozaki K, Nakamura H, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet. 1998;19(4):323-324. doi:10.1038/1209. PMID: 9697690.
66. Wali GN, Halliday D, Dua J, Ieremia E, McPherson T, Matin RN. Cutaneous hyperpigmentation and familial gastrointestinal stromal tumour associated with KIT mutation. Clin Exp Dermatol. 2019;44(4):418-421. doi:10.1111/ced.13757. PMID: 30280421.
67. Online Mendelian Inheritance in Man, OMIM®. #606764 Gastrointestinal stromal tumor. Baltimore (MD): Johns Hopkins University; [accessed 2026-10-29]. Available from: https://omim.org/entry/606764
68. GeneGuidance. KITLG — clinical gene curation. [accessed 2026-10-29].
69. Giacaman A, Martín-Santiago A. [Translated article] Piebaldism. Actas Dermosifiliogr. 2025;116(8):T919. doi:10.1016/j.ad.2025.06.008. PMID: 40562165.
70. Oliveira BA, Torres A, Ricci-Júnior E, Almeida IF, Monteiro MSSB. Topical Treatments for Rare Genetic Dermatological Diseases: A Narrative Review. Pharmaceuticals (Basel). 2025;18(11):1762. doi:10.3390/ph18111762. PMID: 41305004. PMC12655290.
71. Stevens CA, Chiang PW, Messiaen LM. Café-au-lait macules and intertriginous freckling in piebaldism: clinical overlap with neurofibromatosis type 1 and Legius syndrome. Am J Med Genet A. 2012;158A(5):1195-1199. doi:10.1002/ajmg.a.35297. PMID: 22438235.
72. Hegde SS, Srinivas SM, Nanjundappa N. KIT Gene Mutation Causing Piebaldism Associated with Multiple Café Au-Lait Like Macules and Freckling: Delineating a Cause of this Coexistence. Indian Dermatol Online J. 2023;14(2):240-244. doi:10.4103/idoj.idoj_368_22. PMID: 37089832. PMC10115335.
73. Chiu YE, Dugan S, Basel D, Siegel DH. Association of Piebaldism, multiple café-au-lait macules, and intertriginous freckling: clinical evidence of a common pathway between KIT and sprouty-related, ena/vasodilator-stimulated phosphoprotein homology-1 domain containing protein 1 (SPRED1). Pediatr Dermatol. 2013;30(3):379-382. doi:10.1111/j.1525-1470.2012.01858.x. PMID: 23016555. PMC3967413.
74. Duarte A, Mota A, Baudrier T, Morais P, Santos A, Cerqueira R, et al. Piebaldism and neurofibromatosis: state of knowledge. Dermatol Online J. 2013;19(1):17. doi:10.5070/d39hm4n1kg. PMID: 23374959.
75. Park SY, Kim HJ, Ahn SK. Piebaldism with neurofibromatosis type I: a familial case. Ann Dermatol. 2014;26(2):264-266. doi:10.5021/ad.2014.26.2.264. PMID: 24882989. PMC4037687.
76. Spritz R. Letter: Misdiagnosis of "neurofibromatosis" in patients with piebaldism. Dermatol Online J. 2011;17(11):13. PMID: 22136869.
77. Spritz RA, Itin PH, Gutmann DH. Piebaldism and neurofibromatosis type 1: horses of very different colors. J Invest Dermatol. 2004;122(2):xxxiv-xxxv. doi:10.1046/j.0022-202x.2004.22235.x. PMID: 15009761.
78. Takahashi M, Hida T, Okura M, Ishikawa A, Kobayashi M, Uhara H. Piebaldism with café-au-lait macules in a fair-skinned infant: a diagnostic pitfall in the differential diagnosis of NF1 and Legius syndrome. Eur J Dermatol. 2026;36(5):456-457. doi:10.1684/ejd.2026.5137. PMID: 42862178.
79. Gironi LC, Colombo E, Brusco A, Grosso E, Naretto VG, Guala A, et al. Congenital Sensorineural Hearing Loss and Inborn Pigmentary Disorders: First Report of Multilocus Syndrome in Piebaldism. Medicina (Kaunas). 2019;55(7):E345. doi:10.3390/medicina55070345. PMID: 31284637. PMC6681376.
80. Ju HJ, Bae JM. Vitiligo and Its Mimics in Childhood: A Diagnostic Framework for Hypopigmented Disorders. Ann Dermatol. 2026;38(5):360-374. doi:10.5021/ad.26.064. PMID: 42845200. PMC13655464.
81. Tosaki H, Kunisada T, Motohashi T, Aoki H, Yoshida H, Kitajima Y. Mice transgenic for Kit(V620A): recapitulation of piebaldism but not progressive depigmentation seen in humans with this mutation. J Invest Dermatol. 2006;126(5):1111-1118. doi:10.1038/sj.jid.5700173. PMID: 16456533.
82. Frances L, Betlloch I, Leiva-Salinas M, Silvestre JF. Spontaneous repigmentation in an infant with piebaldism. Int J Dermatol. 2015;54(6):e244-6. doi:10.1111/ijd.12776. PMID: 25773601.
83. Matsunaga H, Tanioka M, Utani A, Miyachi Y. Familial case of piebaldism with regression of white forelock. Clin Exp Dermatol. 2008;33(4):511-512. doi:10.1111/j.1365-2230.2008.02703.x. PMID: 18355360.
84. Gaudiello F, Ferrillo M, Vastarella M, Fabbrocini G, Patrì A. Repigmentation of White Forelock in a Familial Case of Piebaldism Reported via Teledermatology in the COVID-19 Era. Skin Appendage Disord. 2021;7(2):120-122. doi:10.1159/000512033. PMID: 33791342. PMC7801991.
85. Davis BK, Verdol LD. Expansion and contraction of hypomelanotic areas in human piebaldism. Hum Genet. 1976;34(2):163-170. doi:10.1007/bf00278885. PMID: 1002140.
86. Herranz P, Borbujo J, Martínez W, Vidaurrázaga C, Diaz R, Casado M. Rubinstein-Taybi syndrome with piebaldism. Clin Exp Dermatol. 1994;19(2):170-172. doi:10.1111/j.1365-2230.1994.tb01152.x. PMID: 8050153.
87. Finucane B, Scott CI, Kurtz MB. Concurrence of dominant piebald trait and fragile X syndrome. Am J Hum Genet. 1991;48(4):815. PMID: 2014804. PMC1682941.
88. Ghoshal B, Sarkar N, Bhattacharjee M, Bhattacharjee R. Glycogen storage disease 1a with piebaldism. Indian Pediatr. 2012;49(3):235-236. doi:10.1007/s13312-012-0048-y. PMID: 22484741.
89. Costa LD, Fixler J, Berets O, Leblanc T, Willig TN, Mohandas N, et al. Piebaldism in diamond-blackfan anaemia: a new phenotype?. Br J Haematol. 2002;119(2):572. doi:10.1046/j.1365-2141.2002.03835_1.x. PMID: 12406103.
90. Köklü S, Ertuğrul D, Onat AM, Karakuş S, Haznedaroğlu IC, Büyükaşik Y, et al. Piebaldism associated with congenital dyserythropoietic anemia type II (HEMPAS). Am J Hematol. 2002;69(3):210-213. doi:10.1002/ajh.10055. PMID: 11891809.
91. Firth HV, Hurst JA. Oxford Desk Reference: Clinical Genetics and Genomics. 2nd ed. Oxford: Oxford University Press; 2017. Deafness in early childhood; p. 122–125.
92. Firth HV, Hurst JA. Oxford Desk Reference: Clinical Genetics and Genomics. 2nd ed. Oxford: Oxford University Press; 2017. Hirschsprung's disease; p. 452–453.
93. Dippel E, Haas N, Grabbe J, Schadendorf D, Hamann K, Czarnetzki BM. Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, naevus depigmentosus and vitiligo. Br J Dermatol. 1995;132(2):182-189. doi:10.1111/j.1365-2133.1995.tb05011.x. PMID: 7534102.
94. Wang C, Zhang Y, Hu X, Wang L, Xu Z, Xing H. Novel pathogenic variants in KIT gene in three Chinese piebaldism patients. Front Med (Lausanne). 2022;9:1040747. doi:10.3389/fmed.2022.1040747. PMID: 36438053. PMC9684607.
95. Shi W, Yang K, Sun Y, Chu Y, Zhang Y, Hao B, et al. A novel c.2326G>A KIT pathogenic variant in piebaldism. Am J Transl Res. 2020;12(10):6501-6508. PMID: 33194047. PMC7653609.
96. Jones KL, Jones MC, del Campo M. Smith's Recognizable Patterns of Human Malformation. 8th ed. Philadelphia: Elsevier; 2022. Waardenburg syndrome; p. 358–361.
97. Mororó GP, Mororó GP, Ribeiro EM. Síndrome de Waardenburg. In: Ribeiro EM, coord. Síndromes Genéticas: Reconhecer para Tratar. Fortaleza: EdUnichristus; 2021. p. 68–70.
98. Eleftheriadou V, Atkar R, Batchelor J, McDonald B, Novakovic L, Patel JV, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022;186(1):18-29. doi:10.1111/bjd.20596. PMID: 34160061.
99. Jones KL, Jones MC, del Campo M. Smith's Recognizable Patterns of Human Malformation. 8th ed. Philadelphia: Elsevier; 2022. Branchio-oculo-facial syndrome; p. 352–353.
100. Tanemura A, Oiso N, Okamura K, Hiroyasu S, Araki Y, Yang L, et al. Second Guidelines for the Diagnosis and Treatment of Vitiligo in Japan (2025). J Dermatol. 2026;53(8):e620-e638. doi:10.1111/1346-8138.70313. PMID: 42219812. PMC13435076.
101. Akarsu S, İlknur T, Avcı C, Fetil E. Piebaldism Associated with Café-au-lait Macules and Intertriginous Freckling: A Case Report and Review of the Literature. Ann Dermatol. 2019;31(5):567-570. doi:10.5021/ad.2019.31.5.567. PMID: 33911651. PMC7992560.
102. Online Mendelian Inheritance in Man, OMIM®. 277740 White forelock with malformations. Baltimore (MD): Johns Hopkins University; [accessed 2026-10-29]. Available from: https://omim.org/entry/277740
103. Narayan VS, van den Bol LLC, van Geel N, Bekkenk MW, Luiten RM, Wolkerstorfer A. Donor to recipient ratios in the surgical treatment of vitiligo and piebaldism: a systematic review. J Eur Acad Dermatol Venereol. 2021;35(5):1077-1086. doi:10.1111/jdv.17108. PMID: 33428279. PMC8247963.
104. Njoo MD, Nieuweboer-Krobotova L, Westerhof W. Repigmentation of leucodermic defects in piebaldism by dermabrasion and thin split-thickness skin grafting in combination with minigrafting. Br J Dermatol. 1998;139(5):829-833. doi:10.1046/j.1365-2133.1998.02508.x. PMID: 9892949.
105. Böhm M, Schunter JA, Fritz K, Salavastru C, Dargatz S, Augustin M, et al. S1 Guideline: Diagnosis and therapy of vitiligo. J Dtsch Dermatol Ges. 2022;20(3):365-378. doi:10.1111/ddg.14713. PMID: 35246935.
106. van Geel N, Wallaeys E, Goh BK, De Mil M, Lambert J. Long-term results of noncultured epidermal cellular grafting in vitiligo, halo naevi, piebaldism and naevus depigmentosus. Br J Dermatol. 2010;163(6):1186-1193. doi:10.1111/j.1365-2133.2010.10014.x. PMID: 20804490.
107. Selmanowitz VJ, Rabinowitz AD, Orentreich N, Wenk E. Pigmentary correction of piebaldism by autografts. I. Procedures and clinical findings. J Dermatol Surg Oncol. 1977;3(6):615-622. doi:10.1111/j.1524-4725.1977.tb00368.x. PMID: 338655.
108. Falabella R, Barona M, Escobar C, Borrero I, Arrunategui A. Surgical combination therapy for vitiligo and piebaldism. Dermatol Surg. 1995;21(10):852-857. doi:10.1111/j.1524-4725.1995.tb00711.x. PMID: 7551740.
109. Olsson MJ, Juhlin L. Epidermal sheet grafts for repigmentation of vitiligo and piebaldism, with a review of surgical techniques. Acta Derm Venereol. 1997;77(6):463-466. doi:10.2340/0001555577463466. PMID: 9394984.
110. Bondanza S, Bellini M, Roversi G, Raskovic D, Maurelli R, Paionni E, et al. Piebald trait: implication of kit mutation on in vitro melanocyte survival and on the clinical application of cultured epidermal autografts. J Invest Dermatol. 2007;127(3):676-686. doi:10.1038/sj.jid.5700639. PMID: 17124503.
111. Komen L, Vrijman C, Prinsen CA, van der Veen JP, Luiten RM, Wolkerstorfer A. Optimising size and depth of punch grafts in autologous transplantation of vitiligo and piebaldism: a randomised controlled trial. J Dermatolog Treat. 2017;28(1):86-91. doi:10.1080/09546634.2016.1179251. PMID: 27309418.
112. Maghfour J, Bardhi R, Huggins R, Hamzavi IH, Mohammad TF. Recipient-to-Donor Ratios in the Surgical Treatment of Vitiligo, Leukoderma, and Piebaldism: A Retrospective Review. Dermatology. 2023;239(5):828-831. doi:10.1159/000530930. PMID: 37231873.
113. Jin R, Hong W, Ye Z, Fu L, Hu W, Xu A. Comparative outcomes of autologous cultured melanocytes transplantation and non-cultured epidermal cell suspension transplantation in piebaldism patients: A retrospective study. Skin Res Technol. 2024;30(1):e13580. Retraction in: Skin Res Technol. 2025;31(9):e70226. doi:10.1111/srt.13580. PMID: 38225879. PMC10790057.
114. Retraction: Comparative Outcomes of Autologous Cultured Melanocytes Transplantation and Non-Cultured Epidermal Cell Suspension Transplantation in Piebaldism Patients: A Retrospective Study. Skin Res Technol. 2025;31(9):e70226. doi:10.1111/srt.70226. PMID: 40964891. PMC12444424.
115. Bhingradia YM, Gupta S, Ghia D, Shah S, Patel NK, Salim T, et al. Consensus statement on the surgical management of vitiligo. J Cutan Aesthet Surg. 2025;18(1):27-33. doi:10.25259/jcas_117_2024. PMID: 40027541. PMC11866675.
116. ClinicalTrials.gov. Search: condition = piebaldism [Internet]. Bethesda (MD): National Library of Medicine; [accessed 2026-10-29]. Available from: https://clinicaltrials.gov/search?cond=piebaldism
117. Komen L, Vrijman C, Tjin EP, Krebbers G, de Rie MA, Luiten RM, et al. Autologous cell suspension transplantation using a cell extraction device in segmental vitiligo and piebaldism patients: A randomized controlled pilot study. J Am Acad Dermatol. 2015;73(1):170-172. doi:10.1016/j.jaad.2015.03.036. PMID: 26089056.
118. Bertolotti A, Leone G, Taïeb A, Soriano E, Pascal M, Maillard H, et al. Assessment of Non-cultured Autologous Epidermal Cell Grafting Resuspended in Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism Lesions: A Randomized Clinical Trial. Acta Derm Venereol. 2021;101(7):adv00506. doi:10.2340/00015555-3870. PMID: 34230975. PMC9413657.
119. Nasr MI, Mostafa AM, Bashtar M, Elsaadany AE. Rapid Complete Repigmentation in Piebaldism Using Noncultured Epidermal Cell Suspension. Dermatol Surg. 2025;51(9):912-913. doi:10.1097/dss.0000000000004634. PMID: 40152360.
120. Chen YJ, Diao P, Wan RY, Li L. Piebaldism resulting from a novel deletion mutation of KIT gene in a five-generation Chinese family. Clin Exp Dermatol. 2022;47(1):232-234. doi:10.1111/ced.14834. PMID: 34374464.
121. Zhu L, Yang C, Zhong W, Huang YQ, Zhang Q, Xu WC, et al. KIT-related piebaldism in a Chinese girl. Am J Med Genet A. 2020;182(6):1321-1328. doi:10.1002/ajmg.a.61576. PMID: 32220041.
122. Agarwal S, Ojha A. Piebaldism: A brief report and review of the literature. Indian Dermatol Online J. 2012;3(2):144-147. Retraction in: Indian Dermatol Online J. 2024;15(3):569. doi:10.4103/2229-5178.96722. PMID: 23130293.
123. Nagatani K, Okamura K, Katagiri K, Ono R, Nishigori C, Araki Y, et al. Report of two Japanese patients with piebaldism including a novel mutation in KIT. J Dermatol. 2021;48(2):e94-e95. doi:10.1111/1346-8138.15684. PMID: 33155701.
124. Kerkeni E, Boubaker S, Sfar S, Bizid M, Besbes H, Bouaziz S, et al. Molecular characterization of piebaldism in a Tunisian family. Pathol Biol (Paris). 2015;63(3):113-116. doi:10.1016/j.patbio.2015.03.004. PMID: 25910686.
125. Diop K, Ndiaye MT, Paglan EP, Diassé F, Lana Y, Diadie S, et al. Piebaldism: 3 cases in African children, including two twin sisters. Ann Dermatol Venereol. 2025;152(4):103407. doi:10.1016/j.annder.2025.103407. PMID: 40834465.
126. Neves DR, Régis Júnior JR, Oliveira PJ, Zac RI, Silveira Kde S. Melanocyte transplant in piebaldism: case report. An Bras Dermatol. 2010;85(3):384-388. doi:10.1590/s0365-05962010000300016. PMID: 20676476.